Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRINCIPAL
- Sponsors GlaxoSmithKline; Novartis
- 12 Jul 2017 Status changed from recruiting to completed.
- 02 Feb 2017 Status changed from active, no longer recruiting to recruiting.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.